The systemic immune-inflammation index (SII = N × P/L) based on neutrophil (N), platelet (P) and lymphocyte (L) counts is used to predict the survival of patients with malignant tumours and can fully reflect the balance between host inflammatory and immune status. This study is conducted to explore the potential prognostic significance of SII in patients with breast cancer undergoing neoadjuvant chemotherapy (NACT). A total of 262 patients with breast cancer received NACT were enrolled in this study. According to the receiver operating characteristic curve, the optimal cutoff value of SII was divided into two groups: low SII group (<602 × 10 9 /L) and high SII group (≥602 × 10 9 /L). The associations between breast cancer and clinicopathological variables by SII were determined by chi-squared test or Fisher's exact test. The Kaplan-Meier plots and log-rank test were used to determine clinical outcomes of disease-free survival (DFS) and overall survival (OS). The prognostic value of SII was analysed by univariate and multivariate Cox proportional hazards regression models.
| INTRODUC TI ON
Breast cancer is one of the most frequent female malignancies and is the second cause of morbidity and mortality in women all over the world. 1 In recent years, the incidence of breast cancer is increasing year after year, and the number of breast cancer survivors sustains growth. 2 Moreover, 1.67 million new breast cancer cases and 522 000 deaths of breast cancer are reported worldwide per year, and the age of onset tends to be younger. 3 In China, breast carcinoma is the leading major cause of cancer-related mortality for females and has the highest incidence rate. 4 The incidence of breast carcinoma is increasing rapidly in coastal developed cities, and the post-menopausal breast cancer patients in China will reach 100/100 000 in the future. 5 Because of the progress of early diagnosis and the improvement of treatment strategy, lots of patients have been successfully treated, and the average 5-year survival rate is around 90%. 6 However, approximately 20%-25% patients are diagnosed with locally advanced breast cancer, and these patients account for early relapse and deaths. 7, 8 A large number of studies have proved that surgery combined with adjuvant chemotherapy and radiotherapy can effectively improve the survival rate of patients according to the progress of early detection and treatment. [9] [10] [11] Neoadjuvant chemotherapy (NACT) is widely used to the treatment for breast cancer and has been testified to be beneficial for breast cancer patients. The application of neoadjuvant chemotherapy in breast cancer has attracted more and more attention as a result of increasing breast-conserving surgery rate in patients who might have required a mastectomy at initial diagnosis and decreasing tumour stage to achieve surgical operation chance and not increasing post-operative recurrence risk. 12, 13 The main purpose of NACT is to establish a therapeutic strategy based on proven therapeutic efficacy and reduce the size of tumours and improve breast-conserving rates. 14, 15 Although a number of NACT regimens have been used to treat the breast cancer, there is no internationally generally accepted NACT regimen for advanced breast carcinoma. 16, 17 Therefore, it is necessary to seek some sensitive and effective indicators of breast carcinoma in order to improve the long-term survival and provide better treatment measures.
There are some factors influencing the prognosis of the breast carcinoma, for instance, pathological stage, histologic type, molecular subtypes, tumour size, lymph vessel invasion, menopause age and so forth. 18 Some histologic and immunologic indicators are used for assessing the prognosis of breast carcinoma. These indicators depend heavily on primary tumour samples, are often expensive, strenuous and taking a lot of time and are usually limited their use in clinical practice. 19 To a greater extent, it is complicated when some variable factors are taken into consideration such as ER status, PR status, Ki-67 status, HER2 status of breast carcinoma or post-operative adjuvant treatment. Consequently, it is important to develop clinically easily reliable and accessible biomarkers to stratify the prognosis of patients with breast cancer.
In recent years, inflammation has been suggested as a critical and potentially intervenable mechanism in the pathogenesis of patients with carcinoma. Tumour associated inflammation is a fundamental part of the tumour microenvironment and could be responsible for treatment response. The changes in inflammatory cells may affect tumour carcinogenesis, development and metastasis, for example neoplastic cell proliferation, invasion migration and metastasis. 20 The detection of peripheral blood can reflect the inflammatory state of tumours for the diagnosis and treatment of tumours. A large number of studies have clarified that the elevated inflammatory biomarkers, for instance, white blood cell (W), neutrophil (N), lymphocyte (L), monocyte (M), platelet counts (P), C-reactive protein (CRP), as well as neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), lymphocyte-to-monocyte ratio (LMR) and systemic inflammation response index (SIRI), are detected in the systemic circulation and widely considered as prognostic factors for many malignant tumours. [21] [22] [23] [24] An integrated and novel indicator that named systemic immune-inflammation index (SII = N × P/L), which is based on neutrophil (N), platelet (P) and lymphocyte (L) counts, is demonstrated to be related to clinical outcomes and predict the survival time of patients with cancer. 25, 26 This integrated indicator may fully reflect the balance between host inflammatory and immune status compared with NLR, LMR/MLR and PLR and other conventional haematological parameters. However, the SII has been studied rarely in breast cancer patients received NACT. As far as we are concerned, the relationship between SII and breast cancer has not breast cancer patients with low SII value had better prognosis and lower recurrence rates than those with high SII value. Pre-treatment SII with the advantage of reproducible, convenient and non-invasive was a useful prognostic indicator for breast cancer patients undergoing neoadjuvant chemotherapy and is a promising biomarker for breast cancer on treatment strategy decisions.
K E Y W O R D S
breast cancer, neoadjuvant chemotherapy, prognosis, survival, systemic immune-inflammation index (SII) been building-up. Hence, the purpose of this study is to investigate the prognostic significance of SII in patients with breast cancer undergoing NACT.
| MATERIAL S AND ME THODS

| Study population
The retrospective analysis was enrolled 262 patients with advanced breast carcinoma undergoing NACT at Cancer Hospital Chinese Academy of Medical Sciences from January 1999 to December 2014. All patients were confirmed in accordance with the histology by core needle biopsy, and all cases were received NACT treatment.
The details of treatment for all patients were extracted from the patients' medical record. This study was approved by the ethics com- 
| Chemotherapy regimens
We used anthracyclines-based and/ or taxanes-based neoadjuvant chemotherapy regimens, and one cycle of these regimens was re- On the first day, Anthracyclines (Zhejiang Hisun Pharmaceutical Co., LTD) at 90 mg/m 2 was given by intravenous injection in 100 mL of 0.9% Normalsaline, and Cyclophosphamide (Baxter Oncology GmbH, Halle, Germany) at 600 mg/m 2 was given by intravenous injection in 100 mL of 0.9% Normalsaline. One cycle of this regimen was repeated every 3 weeks. ACF regimen: A: 90 mg/m 2 , C: 600 mg/m 2 , (5-Fluorouracil, F): 500 mg/m 2 .
On the first day, Anthracyclines at 90 mg/m 2 was given by intravenous injection in 100 mL of 0.9% Normalsaline, and Cyclophosphamide at 600 mg/m 2 was given by intravenous injection in 100 mL of 0.9% Normalsaline. From the first day to the second day, 5-Fluorouracil (Tianjin Jinyao Pharmaceutical Co., LTD) 500 mg/m 2 was given by intravenous injection in 500 mL of 5% glucose above 46 h. One cycle of this regimen was repeated every 3 weeks.
CT regimen: C: 600 mg/m 2 , (Taxol, T): 175 mg/m 2 .
On the first day, Cyclophosphamide at 600 mg/m 2 was given by intravenous injection in 100 mL of 0.9% Normalsaline, and Taxol (Jiangsu Hengrui Medicine Co., Ltd) at 175 mg/m 2 was given by intravenous injection in 500 mL of 0.9% Normalsaline above 3 hours. One cycle of this regimen was repeated every 3 weeks.
ACT regimen: A: 90 mg/m 2 , C: 600 mg/m 2 , T: 175 mg/m 2 .
On the first day, Anthracyclines at 90 mg/m 2 was given by intravenous injection in 100 mL of 0.9% Normalsaline, and Cyclophosphamide at 600 mg/m 2 was given by intravenous injection in 100 mL of 0.9% Normalsaline, Taxol at 175 mg/m 2 was given by intravenous injection in 500 mL of 0.9% Normalsaline above 3 hours.
One cycle of this regimen was repeated every 3 weeks.
AT regimen: A: 90 mg/m 2 , T: 175 mg/m 2 .
On the first day, Anthracyclines at 90 mg/m 2 was given by intravenous injection in 100 mL of 0.9% Normalsaline, and Taxol at 175 mg/m 2 was given by intravenous injection in 500 mL of 0.9% Normalsaline above 3 hours. One cycle of this regimen was repeated every 3 weeks.
TP regimen: T: 175 mg/m 2 , (Platinum compounds, P): AUC 4-6.
On the first day, Taxol at 175 mg/m 2 was given by intravenous injection in 500 mL of 0.9% Normalsaline above 3 hours, and Platinum compounds (Bristol-Myers Squibb biopharmaceutical company, Srl.) at AUC 4-6 was given by intravenous injection in 500 mL of 0.9% Normalsaline or 500 mL of 5% glucose. One cycle of this regimen was repeated every 3 weeks.
| Classification criteria and response evaluation
The tumour size was determined by the maximum diameter of the sample. TNM stage system was performed by the eighth edition of the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) TNM stage classification. 27, 28 Pathology type was classified as ductal carcinoma, lobular carcinoma and others. Molecular subtypes of breast cancer were divided into Luminal A, Luminal B HER2-positive, Luminal B HER2-negative, HER2-enriched and Triple negative. 29 The histologic response was estimated on the basis of Miller and Payne grade (MPG), and the MPG was categorized into five grades in line with the number of tumour cells in excision/ mastectomy specimens compared with the pretreatment core biopsy as follows 30 :(a) grade 1, no reduction in total number of cancer cells; (b) grade 2, minor (<30%) loss of total number of cancer cells; (c) grade 3, estimated 30%-90% reduction in total number of cancer cells; (d) grade 4, over (>90%) loss of total number of cancer cells; 5) grade 5, no infiltrating cancer (IC), or ductal carcinoma in situ. Histologic tumour grade was accessed by the Elston-Ellis modification of Scarff-Bloom-Richardson grading system and based on three factors, 31 such as: (a) the amount of gland formation; (b) the nuclear features; and (c) the mitotic activity. Each feature score was 1-3 points and then added the score to get the final total score of 3-9 points and was categorized into three grades by the following way 32 :
(a) grade I, the total score of tumours was 3-5 points; (b) grade II, the total score of tumours was 6-7 points; (c) grade III, the total score of tumours was 8-9 points. The response rate was defined in the light of the Response Evaluation Criteria In Solid Tumours (RECIST) guidelines and was stratified into four groups: complete response (CR), partial response (PR), stable disease (SD) and progression of disease (PD). 33 The sum of CR and PR were the clinical objective response rate, the sum of SD and PD were the non-clinical response rate, and the sum of CR, PR and SD were the clinical benefit rate. Lymph vessel invasion and neural invasion were diagnosed by haematoxylin and eosin (HE) stain. The toxicity of NACT was accessed on the basis of the National Cancer Institute Common Toxicity Criteria (NCICTC). 34 
| Peripheral venous blood parameters
Peripheral venous blood samples were taken within 1 week after breast cancer diagnosis and before neoadjuvant chemotherapy. The sterile EDTA tube was used to collect the blood samples. The XE-2100 haematology analyser (Sysmex, Kobe, Japan) was used to analyse the haematological parameters.
| Follow-up
All enrolled patients had post-operative follow-up in inpatients or outpatients every 3 months for the 1st to 2nd year, every 6 months for the 3rd to 5th year after surgery, then annually every year and until death. 35 Follow-up assessments included laboratory tests (routine blood test, analyses. The clinicopathologic categorical variables were performed as frequencies and percentages (%), and the associations between breast carcinoma and clinicopathological variables were evaluated by chi-squared test or Fisher's exact test. The Kaplan-Meier product limit estimator method was to determine the survival time of DFS and OS, and the association between breast carcinoma and survival was analysed by the Kaplan-Meier plots and log-rank test. The Cox proportional hazards regression model was used to examine the independent prognostic factors. P < .05 was considered to be statistical significance.
| Statistical analysis
| RE SULTS
| Demographic and clinicopathologic characteristics of all breast cancer patients
Two hundred and sixty two patients with breast carcinoma were included in this study. The clinicopathological characteristics of patients with breast cancer were shown in Table 1 . The ROC analysis was intended for evaluating the optimal cut-off value of the SII (602 × 10 9 /L).
Hence, the patients were categorized into two groups: low SII group (<602 × 10 9 /L) and high SII group (≥602 × 10 9 /L). All cases were females, and the median age was 48 years, with the range from 27 to (Table 1 ). In our study, patients with low SII value were significantly associated with menopause (χ 2 = 5.723, P = .016), US-LNM (χ 2 = 4.331, P = .037).
| Relationships between SII and haematological parameters
In our study, the optimal cut-off value of SII was decided as 602 × 10 9 /L, which was calculated considering the maximum (sen- mL, and 6.00 × 10 9 /L, 4.34 × 10 9 /L, 128.00 × 10 9 /L, 3.83 × 10 9 /L, 1.67 × 10 9 /L, 0.34 × 10 9 /L, 244.00 × 10 9 /L, 2.50, 0.22, 160.00, respectively. A low SII was significantly related to ALB (P = .001), CRP (P = .042), CA125 (P = .044), W (P < .001), R (P = .024), Hb (P = .026), N (P < .001), P (P = .001), NLR (P < .001), MLR (P < .001), PLR (P < .001).
( Table 2 ).
| Association of SII and neoadjuvant chemotherapy or post-operative chemotherapy
All enrolled patients received NACT treatment, and the median number of pre-operative chemotherapy was six times, and 27 pa- 
| Correlation between SII and breast cancer molecular subtypes
| Correlation between SII and side effects of chemotherapy
In our study, the side effects of neoadjuvant chemotherapy for two cycles were evaluated and analysed by NCICTC. We also found that were the haematological and gastrointestinal reaction were the common toxicities after NACT. 
| Univariate and multivariate Cox regression survival analyses
The median DFS and OS of all enrolled patients were 36.85 months (range 4.00-197.97 months) and 49.95 months (range 5.93-250.97 months), respectively ( Figure 1A, 1) . 20 .8% (22/106), 6.6% (7/106), respectively. The results also indicated that the incidence of DFS and OS in patients with low SII was higher than that in patients with high SII in 3-, 5-and 10-year rates.
| Survival rate and prognostic significance of SII
Although there was a trend towards significance for the association between low SII and high SII at 3-, 5-and 10-year rates, there were no significant differences between the two groups. (Table 7 , Figure 2A -D).
| Association of molecular subtypes by postoperative pathology IHC and SII in patients with breast carcinoma
The results showed that molecular subtypes by post-operative pathology IHC were the important prognostic factor ( Table 6 ). In order to go deep into evaluating the prognostic value of SII, the SII was analysed by the molecular subtypes. And the SII with different mo- 
| Correlation between Miller and Payne grade (MPG) and SII in breast cancer patients
According to univariate and multivariate analyses, the MPG was the significant prognostic factor ( Figure 4A 
| Association of ER status and SII in patients with breast carcinoma
The results indicated that ER status in both core needle biopsy and post-operative pathology IHC was the significant prognostic factor.
Hence, for the sake of further to study the prognostic efficiency of SII, the SII was analysed by ER status. In core needle biopsy, the mean DFS and OS time in patients with low SII by the log-rank test were longer than in those patients with high SII in ER negative (χ 2 = 5.401, P = .020 and χ 2 = 5.476, P = .019, respectively; Figure 5A 
| Correlation between Ki-67 status and SII in breast cancer patients
| Association of lymph vessel invasion and SII in breast cancer patients
The results also proved that lymph vessel invasion was the significant prognostic factor by univariate and multivariate analyses ( Table 6 ). The results showed that the mean DFS and OS time in patients with low SII by the log-rank test were longer than in those patients with high SII in patients without lymph vessel invasion (χ 2 = 4.438, P = .035 and χ 2 = 4.817, P = .028, respectively; Figure 7A, 7) . And the results also indicated that the mean DFS and OS time in patients with low SII by the log-rank test were longer than in those patients with high SII in patients with lymph vessel invasion (χ 2 = 0.359, P = .549 and χ 2 = 0.241, P = .623, respectively; Figure 7C, 7) . 
Parameters
| D ISCUSS I ON
Breast carcinoma is the most common diagnostic cancer and with more than 2.1 million newly diagnosed female breast cancer cases in 2018, accounting for almost one in four cancer cases among women. 36 The surgery, radiotherapy and endocrine therapy are used to the treatment of early breast cancer; however, the neoadjuvant treatment which can turn inoperable tumours into operable tumours or reduce tumour stage for more frequent conservative breast surgery. 37 Meanwhile, NACT allows rapid assessment of drug efficacy, and the clinical outcomes and quality of life for patients with breast cancer have greatly improved, especially in TNBC. 38 Hence, it is very important to look for precise predictors to choose the best treatment options and improve clinical outcomes for breast cancer patients.
Peripheral venous blood analysis can proclaim the condition of the whole immune system. Some studies have indicated the association between the systemic inflammation and malignant tumours. [39] [40] [41] [42] The neutrophils, monocytes, platelets and lymphocytes are associated with the prognosis of different kinds of cancer. Neutrophils are a maker of inflammatory and immune response and influence tumour development, progression and metastasis via restraining inflammatory factors, such as neutrophil elastase, matrix metalloproteinase-9 (MMP-9), nuclear factor-κB (NF-kB), vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) have been clarified. [43] [44] [45] [46] [47] Monocytes play an important role in tumour angiogenesis, inflammatory response and metastases and can create an environment of chronic oxidative stress, such as oncostain-M, VEGF has been proved. [48] [49] [50] Platelets have been found to contribute to an indicator of tumour activity, and relate to growth, invasion and metastasis of the primary tumour; and platelet release promotes cancer cell proliferation mainly through VEGF-integrin cooperative signalling. [51] [52] [53] However, lymphocytes are involved in the prevention of tumour proliferation, and the lymphocyte response is an important component of anticancer immunity and immune surveillance, as well as lymphocytes are implicated in the killing of cancer cells and increased chemotherapy responsiveness, and correlates with better survival in cancer patients. [54] [55] [56] [57] Numerous studies showed that inflammatory markers and immune-based prognostic indexes, such as NLR, d-NLR, MLR/LMR and PLR, were considered to have prognostic value for breast cancer. [58] [59] [60] [61] [62] [63] [64] [65] [66] However, SII based on three inflammatory cells, including neutrophil, platelet and lymphocyte and can fully reflect the balance between host immune and inflammatory status. SII has been investigated in some malignancies, such as gastric cancer, prostate cancer, lung cancer and pancreatic cancer, and SII has been proved to be an independent predictor of malignant tumours. [67] [68] [69] [70] In our study, we confirmed that the SII was the significant prognostic factor by univariate and multivariate analyses and could predict survival in breast cancer patients receiving NACT.
In our study, the clinicopathologic and demographic characteristics of the 262 patients with breast cancer were enrolled and analysed. The optimal cut-off value of the SII was 602 × 10 9 /L by ROC analysis, and this value was used to the data analysis. The results indicated that the low SII was significantly correlated with menopause and US-LNM. The blood parameters were determined by its median value, and the low SII was significantly correlated with ALB, factors of prognosis. The results determined that SII had prognostic significance by using the cut-off value of 602 × 10 9 /L for DFS and OS time, and patients with low SII had survival longer than those patients with high SII. Meanwhile, the results also indicated that patients with low SII have longer 3-, 5-and 10-year rates of DFS and OS time. Moreover, we also found that molecular subtypes were the significant prognostic factors, and patients with low SII would have better survival outcome than those with high SII in triple negative subtype.
The proliferation activity of tumours is usually determined with immunohistochemical detection of the cell-cycle-specific antigen Ki-67. Some studies have proved that Ki-67 expression is a useful prognostic factor in breast cancer. 71, 72 Our results also indicated that Ki-67 status in post-operative pathology IHC was the significant prognostic factor, and patients with low SII would have survive longer than those with high SII by Ki-67 status. And further to study the ER status, patients with low SII would survival longer than those patients with high SII by ER negative. The MPG was used to evaluate the histologic response, MPG was the significant prognostic factor, and patients with high MPG grade would survival longer than those with low MPG grade on DFS and OS time. Lymphatic vessel is confided to play a passive role in tumour metastasis, such as the provision of a niche for cancer stem cells and the modulation of antitumour immune responses. 73 And tumour angiogenesis and its indicator blood vessel density are closely related to the prognosis in breast cancer. 74 In our study, the results indicated that the DFS and OS time in patients with low SII would have survival longer than those patients with high SII by lymph vessel invasion.
This study has several limitations. Firstly, this study is a retro- are needed to support our findings, and the SII may be used in combination with other biomarkers to help predict clinical outcome in patients with breast cancer and is adopted in routine practice.
| CON CLUS IONS
SII is the significant prognostic factor for patients with breast cancer and can effectively predict the survival in patients with breast cancer receiving NACT. It is very important to consider the high incidence of breast cancer and the unbalanced distribution of medical condition in China and that reproducible, conveniently and non-invasive biomarkers should be applied to the prevention and treatment of breast cancer. It is very critical and meaningful to understand of haematological parameters and look for new targets for subjective treatment.
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